KAO Antibody

What is KAO antibody and what biological targets does it recognize?

KAO antibody is a rabbit polyclonal antibody that targets a membrane glycoprotein expressed in epithelium-rich and hematopoietic tissues. The antibody recognizes a specific region within amino acids 1-149 of human ABP1, which functions as an oxidative deaminase for compounds like putrescine and histamine. This protein plays a significant role in controlling histamine and/or putrescine levels in various tissues .

The polyclonal nature of this antibody means it recognizes multiple epitopes on the target protein, providing robust detection capabilities across different experimental applications. When designing experiments with KAO antibody, researchers should consider the glycoprotein's membrane localization and tissue expression patterns for optimal results.

What validated applications can KAO antibody be reliably used for?

KAO antibody has been validated for two primary applications:

• Western Blotting (WB): Recommended dilution range of 1:500-1:3000

• Immunohistochemistry (IHC): Recommended dilution range of 1:50-1:500

These applications have been experimentally validated as demonstrated by the supporting evidence in the product datasheet showing:

• Successful detection of the predicted 85kD protein in Hep G2 cell lysates via Western blot

• Effective immunohistochemical staining in paraffin-embedded Cal27 xenograft samples

When establishing new experimental protocols, these validated applications provide a solid foundation, though optimization for specific experimental conditions is always recommended.

What are the optimal storage and handling conditions for KAO antibody?

For maximum antibody stability and performance:

• Long-term storage: Maintain at -20°C (recommended)

• Short-term use: Store at 4°C

• Formulation: The antibody is supplied in 0.1M Tris-buffered saline with 10% Glycerol (pH 7.0) and 0.01% Thimerosal as a preservative

Proper handling is critical for maintaining antibody activity. Avoid repeated freeze-thaw cycles by aliquoting the antibody upon receipt. When retrieving from storage, thaw on ice and briefly centrifuge before opening to ensure all material is at the bottom of the tube.

How should experimental controls be designed when working with KAO antibody?

Robust experimental design requires appropriate controls to ensure valid interpretation of results:

Additionally, when performing IHC, include tissue sections processed identically but with primary antibody omitted to identify any non-specific binding of secondary antibodies.

What troubleshooting approaches are recommended when KAO antibody shows inconsistent results?

When facing variability in experimental outcomes, systematic troubleshooting is essential:

• Antibody Concentration: Titrate across a wider range than recommended (e.g., 1:250-1:5000 for WB)

• Incubation Conditions: Vary both temperature (4°C, room temperature) and duration (1 hour to overnight)

• Buffer Optimization: Test different blocking agents (BSA, milk, serum) and varying concentrations

• Sample Preparation: Ensure complete denaturation for WB or proper fixation for IHC

• Antigen Retrieval: For IHC, compare heat-induced epitope retrieval methods (citrate vs. EDTA buffers)

Document all optimization steps systematically to identify the critical variables affecting performance in your specific experimental system.

How does KAO antibody compare to other antibody formats in experimental applications?

While KAO is a conventional polyclonal antibody, researchers should consider how it compares to other antibody formats:

VHH antibodies represent an innovative approach as demonstrated by Kao Corporation's work on SARS-CoV-2 neutralizing antibodies, where their small size enables efficient nasal delivery and effective binding to viral spike proteins .

How might protein modifications affect KAO antibody binding and experimental outcomes?

Post-translational modifications (PTMs) of target proteins can significantly impact antibody recognition:

• Phosphorylation: If phosphorylation sites exist within amino acids 1-149 of ABP1, they may enhance or hinder antibody binding depending on epitope location

• Glycosylation: As the target is a membrane glycoprotein, altered glycosylation patterns may affect antibody accessibility

• Proteolytic Processing: Cleavage events could remove epitopes or create new ones not recognized by KAO

• Denaturation State: Since KAO was raised against a recombinant protein fragment, it may preferentially recognize denatured epitopes in WB but perform differently in applications with native proteins

To address these concerns, researchers should consider complementary detection methods and perform experiments under conditions that account for the relevant modifications present in their biological system.

What methodological considerations apply when integrating KAO antibody into advanced bioinformatics approaches?

Modern antibody research increasingly incorporates computational methods:

• Epitope Prediction: Computational analysis can identify potential binding sites of KAO on the target protein structure

• Cross-Reactivity Assessment: Sequence homology searches can predict potential off-target binding

• Machine Learning Integration: As demonstrated in antibody-antigen binding research, machine learning models can predict interactions between antibodies and target antigens

• Active Learning Frameworks: Recent advances show that active learning strategies can improve antibody-antigen binding prediction, potentially reducing experimental costs by up to 35% compared to random sampling approaches

These computational approaches are particularly valuable when experimental data is limited or expensive to generate, allowing researchers to prioritize the most informative experiments.

How can KAO antibody be incorporated into emerging high-throughput or single-cell analysis techniques?

Integration of KAO antibody into cutting-edge technologies requires specific methodological adaptations:

• Single-Cell Proteomics: Conjugation of KAO with fluorophores or metal isotopes for compatibility with mass cytometry (CyTOF) or multiplexed imaging

• Microfluidic Applications: Optimization of antibody concentration and incubation parameters for reduced-volume systems

• Library-on-Library Screening: As described in recent research, antibody-antigen binding can be analyzed in high-throughput library-on-library approaches that generate rich datasets for machine learning models

• High-Performance Computing Integration: Advanced antibody research increasingly relies on computational infrastructure like that described in the UK Innovation Corridor, where high-performance computing facilities support complex immunological data analysis

When adapting KAO antibody for these applications, researchers should validate specificity and sensitivity in the modified format, as binding characteristics may differ from conventional applications.

How has KAO antibody contributed to understanding membrane protein function?

While specific case studies using KAO antibody are not detailed in the provided sources, similar antibody approaches have yielded valuable insights into membrane protein biology:

• Subcellular Localization: IHC applications with KAO can reveal the distribution patterns of the target glycoprotein across different cellular compartments

• Protein-Protein Interactions: KAO can be employed in co-immunoprecipitation studies to identify binding partners of the target membrane glycoprotein

• Expression Profiling: Western blotting with KAO across different tissues can establish expression patterns relevant to physiological function

The successful application of KAO antibody in Cal27 xenograft models suggests its utility in tumor-derived tissues, potentially informing cancer research related to its target protein .

What emerging technologies might enhance KAO antibody applications in the future?

Based on recent developments in antibody technology:

• Cryo-Electron Microscopy: As demonstrated with VHH antibodies against SARS-CoV-2, cryo-EM can reveal precise binding patterns between antibodies and their targets

• Organoid Models: Human-derived organoids provide physiologically relevant systems for studying antibody targeting, as shown in lung-derived alveolar organoids used with VHH antibodies

• Biomanufacturing Advancements: Technologies like those developed by Kao Corporation for VHH antibody production could potentially improve production of other antibody types

• Nasal Delivery Systems: Novel delivery methods developed for therapeutic antibodies might inform new experimental applications for research antibodies like KAO

These technological advances represent opportunities to expand the utility of antibodies in both research and clinical applications.